Trials (University Cancer Institute Toulouse-Oncopole): Revision history

14 December 2025

• curprev 18:4218:42, 14 December 2025‎ Francine talk contribs‎ 73,491 bytes +180‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 73,311 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:5020:50, 2 December 2025‎ Francine talk contribs‎ 71,610 bytes +48‎ No edit summary undo
• curprev 14:0114:01, 2 December 2025‎ Lucas talk contribs‎ m 71,562 bytes +12,940‎ Update categories. undo

4 January 2024

• curprev 18:1918:19, 4 January 2024‎ Francine talk contribs‎ 58,622 bytes +1,197‎ No edit summary undo

1 December 2023

• curprev 22:1022:10, 1 December 2023‎ Francine talk contribs‎ 57,425 bytes +57,425‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to University Cancer Institute Toulouse-Oncopole page '''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced mel..."